WO2001064197A3 - Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives - Google Patents

Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives Download PDF

Info

Publication number
WO2001064197A3
WO2001064197A3 PCT/EP2001/002166 EP0102166W WO0164197A3 WO 2001064197 A3 WO2001064197 A3 WO 2001064197A3 EP 0102166 W EP0102166 W EP 0102166W WO 0164197 A3 WO0164197 A3 WO 0164197A3
Authority
WO
WIPO (PCT)
Prior art keywords
transferase inhibitor
protein transferase
farnesyl protein
anthracycline derivatives
inhibitor combinations
Prior art date
Application number
PCT/EP2001/002166
Other languages
French (fr)
Other versions
WO2001064197A2 (en
Inventor
Mary Ellen Margaret Rybak
Original Assignee
Janssen Pharmaceutica Nv
Mary Ellen Margaret Rybak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv, Mary Ellen Margaret Rybak filed Critical Janssen Pharmaceutica Nv
Priority to CA002397253A priority Critical patent/CA2397253A1/en
Priority to JP2001563094A priority patent/JP2003525237A/en
Priority to AU2001244167A priority patent/AU2001244167A1/en
Priority to EP01917033A priority patent/EP1267872A2/en
Publication of WO2001064197A2 publication Critical patent/WO2001064197A2/en
Publication of WO2001064197A3 publication Critical patent/WO2001064197A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention is concerned with combinations of a farnesyl transferase inhibitor and an anthracycline derivative for inhibiting the growth of tumor cells and useful in the treatment of cancer.
PCT/EP2001/002166 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives WO2001064197A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002397253A CA2397253A1 (en) 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
JP2001563094A JP2003525237A (en) 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with antitumor anthracycline derivatives
AU2001244167A AU2001244167A1 (en) 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
EP01917033A EP1267872A2 (en) 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00200696.3 2000-02-29
EP00200696 2000-02-29

Publications (2)

Publication Number Publication Date
WO2001064197A2 WO2001064197A2 (en) 2001-09-07
WO2001064197A3 true WO2001064197A3 (en) 2002-03-21

Family

ID=8171115

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/002166 WO2001064197A2 (en) 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives

Country Status (5)

Country Link
EP (1) EP1267872A2 (en)
JP (1) JP2003525237A (en)
AU (1) AU2001244167A1 (en)
CA (1) CA2397253A1 (en)
WO (1) WO2001064197A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004028541A2 (en) * 2002-09-27 2004-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Composition for the treatment of nasopharyngeal carcinoma and use thereof
BRPI0417543A (en) 2003-12-12 2007-03-27 Wyeth Corp quinolines useful in treating cardiovascular disease
WO2007075923A2 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
EP2909189B8 (en) 2012-10-16 2017-04-19 Janssen Pharmaceutica NV Heteroaryl linked quinolinyl modulators of ror-gamma-t
EA026415B1 (en) 2012-10-16 2017-04-28 Янссен Фармацевтика Нв METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-t
US9309222B2 (en) 2012-10-16 2016-04-12 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
JP6423423B2 (en) 2013-10-15 2018-11-14 ヤンセン ファーマシューティカ エヌ．ベー． Rorγt alkyl-linked quinolinyl modulator
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
KR20160068956A (en) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. QUINOLINYL MODULATORS OF RORyT

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016443A1 (en) * 1995-10-31 1997-05-09 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 2-quinolone derivatives
WO1997021701A1 (en) * 1995-12-08 1997-06-19 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
WO1998040383A1 (en) * 1997-03-10 1998-09-17 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with n- or c-linked imidazoles
WO1998049157A1 (en) * 1997-04-25 1998-11-05 Janssen Pharmaceutica N.V. Farnesyltransferase inhibiting quinazolinones
WO1999032114A1 (en) * 1997-12-22 1999-07-01 Schering Corporation Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
WO1999065494A1 (en) * 1998-06-15 1999-12-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2000001382A1 (en) * 1998-07-02 2000-01-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2000039082A2 (en) * 1998-12-23 2000-07-06 Janssen Pharmaceutica N.V. 1,2-annelated quinoline derivatives

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016443A1 (en) * 1995-10-31 1997-05-09 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 2-quinolone derivatives
WO1997021701A1 (en) * 1995-12-08 1997-06-19 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
WO1998040383A1 (en) * 1997-03-10 1998-09-17 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with n- or c-linked imidazoles
WO1998049157A1 (en) * 1997-04-25 1998-11-05 Janssen Pharmaceutica N.V. Farnesyltransferase inhibiting quinazolinones
WO1999032114A1 (en) * 1997-12-22 1999-07-01 Schering Corporation Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
WO1999065494A1 (en) * 1998-06-15 1999-12-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2000001382A1 (en) * 1998-07-02 2000-01-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2000039082A2 (en) * 1998-12-23 2000-07-06 Janssen Pharmaceutica N.V. 1,2-annelated quinoline derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIU M ET AL: "Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in huma tumor xenograft models and wap-ras transgenic mice", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 58, no. 21, 1 November 1998 (1998-11-01), pages 4947 - 4956, XP002096891, ISSN: 0008-5472 *
SCHELLENS J H M ET AL: "PHASE I AND PHARMACOLOGIC STUDY WITH THE NOVEL FARNESYLTRANSFERASE INHIBITOR (FTI) R15777", SHIPBUILDING AND SHIPPING RECORD, IP INDUSTRIAL PRESS LTD. LONDON, GB, vol. 40, March 1999 (1999-03-01), pages 724, XP000952727 *

Also Published As

Publication number Publication date
WO2001064197A2 (en) 2001-09-07
AU2001244167A1 (en) 2001-09-12
JP2003525237A (en) 2003-08-26
EP1267872A2 (en) 2003-01-02
CA2397253A1 (en) 2001-09-07

Similar Documents

Publication Publication Date Title
WO2001064198A3 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
WO2001064246A3 (en) Farnesyl protein transferase inhibitor combinations with an her2 antibody
WO2001064195A3 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
WO2001064194A3 (en) Farnesyl protein transferase inhibitor combinations with camptothecin compounds
WO2001064226A3 (en) Farnesyl protein transferase inhibitor combinations with platinum compounds
WO2001064252A3 (en) Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
AU1783800A (en) Combinations of farnesyl transferase inhibitors and irinotecan or camptothecin for treating cancer
WO2001064197A3 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
WO2001064199A3 (en) Farnesyl protein transferase inhibitor combinations with taxane compounds
WO2001064218A3 (en) Farnesyl protein transferase inhibitor combinations
WO2001064217A3 (en) Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
AU2002236527A1 (en) Nutrient supplements and methods for treating autism and for preventing the onset of autism
GR3036188T3 (en) Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase
AU2002213485A1 (en) Inhibitors of protein kinases
AU6622396A (en) 4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors
MY117961A (en) Inhibitors of farnesyl protein transferase
ATE415161T1 (en) FARNESYL PROTEIN TRANSFERASE INHIBITOR IN COMBINATION WITH ANTESTROGENS
AUPQ923100A0 (en) Treatment of prostate cancer
WO2003039545A3 (en) Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
WO2002028381A3 (en) Methods of inducing cancer cell death and tumor regression
AU2477400A (en) Inhibitors of prenyl-protein transferase
AU2002236813A1 (en) Treatment of malaria with farnesyl protein transferase inhibitors
WO2001064196A3 (en) Farnesyl protein transferase inhibitor combinations with vinca alkaloids
WO2000067762A3 (en) Selenium-containing pro-drugs for cancer therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2397253

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 563094

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10220222

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001917033

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001917033

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001917033

Country of ref document: EP